AYTU Overview

Aytu BioPharma, Inc. is a pharmaceutical company focused on advancing medicines for complex central nervous system (CNS) diseases. Its business is focused on the launch of EXXUA and its prescription pharmaceutical products sold primarily through third-party wholesalers and pharmacies and which primarily consists of two product portfolios. Its Attention Deficit Hyperactivity Disorder (ADHD) portfolio consists of Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets (Adzenys) , Cotempla XR-ODT, and METADATE CD, which are CNS stimulants indicated for the treatment of ADHD in patients. Its Pediatric portfolio consists of Karbinal ER (carbinoxamine maleate extended-release oral suspension), an extended-release first-generation antihistamine indicated to treat various allergic conditions including seasonal and perennial allergic rhinitis, vasomotor rhinitis, Poly-Vi-Flor, and Tri-Vi-Flor. EXXUA is indicated to treat depressive disorder (MDD) in adults.

Wall Street analysts forecast AYTU stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AYTU is9.33 USD with a low forecast of 7.00 USD and a high forecast of 13.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Aytu Biopharma Inc revenue for the last quarter amounts to 12.41M USD, decreased -32.74

Aytu Biopharma Inc. EPS for the last quarter amounts to -0.53 USD, decreased -352.38

Aytu Biopharma Inc (AYTU) has 82 emplpoyees as of May 15 2026.

Today AYTU has the market capitalization of 24.15M USD.